These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21287753)

  • 1. [Good effect of valproate against aggression in Huntington disease. Only two cases reported earlier].
    Rask G; Andersson C
    Lakartidningen; 2010 Dec 1-7; 107(48):3060-1. PubMed ID: 21287753
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of Huntington's disease with olanzapine and valproate.
    Grove VE; Quintanilla J; DeVaney GT
    N Engl J Med; 2000 Sep; 343(13):973-4. PubMed ID: 11012330
    [No Abstract]   [Full Text] [Related]  

  • 3. Risperidone as an adjunct to valproic acid.
    Waring EW; Dewan VK; Cohen D; Grewal R
    Can J Psychiatry; 1999 Mar; 44(2):189. PubMed ID: 10097843
    [No Abstract]   [Full Text] [Related]  

  • 4. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
    Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
    Buckley PF; Paulsson B; Brecher M
    J Affect Disord; 2007; 100 Suppl 1():S33-43. PubMed ID: 17376537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial triple therapy of acute mania, adding lithium and valproate to neuroleptics.
    Reischies FM; Hartikainen J; Berghöfer AM
    Pharmacopsychiatry; 2002 Nov; 35(6):244-6. PubMed ID: 12518274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of taunting behavior in vascular dementia with valproic acid.
    Stewart JT; Poetter CE
    J Am Geriatr Soc; 2011 May; 59(5):929-30. PubMed ID: 21568961
    [No Abstract]   [Full Text] [Related]  

  • 8. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia.
    Suzuki T; Uchida H; Takeuchi H; Nakajima S; Nomura K; Tanabe A; Yagi G; Watanabe K; Kashima H
    Hum Psychopharmacol; 2009 Dec; 24(8):628-38. PubMed ID: 19946935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms.
    Zink M; Englisch S; Knopf U; Kuwilsky A; Dressing H
    Pharmacopsychiatry; 2007 Sep; 40(5):202-3. PubMed ID: 17874353
    [No Abstract]   [Full Text] [Related]  

  • 10. Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value?
    Tremolizzo L; Rodriguez-Menendez V; DiFrancesco JC; Sala G; Galbussera A; Appollonio I; Ferrarese C
    Med Hypotheses; 2007; 69(4):964-5. PubMed ID: 17428619
    [No Abstract]   [Full Text] [Related]  

  • 11. Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine.
    Atmaca M; Ozdemir H; Cetinkaya S; Parmaksiz S; Belli H; Poyraz AK; Tezcan E; Ogur E
    J Psychiatr Res; 2007 Nov; 41(10):821-7. PubMed ID: 16950400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive behavior in Huntington's disease: treatment with propranolol.
    Stewart JT; Mounts ML; Clark RL
    J Clin Psychiatry; 1987 Mar; 48(3):106-8. PubMed ID: 2880838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Valproate in the treatment of bipolar disorder].
    Rzewuska M
    Psychiatr Pol; 2002; 36(2):239-57. PubMed ID: 12043042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic ketoacidosis with clozapine treatment.
    Maule S; Giannella R; Lanzio M; Villari V
    Diabetes Nutr Metab; 1999 Apr; 12(2):187-8. PubMed ID: 10554900
    [No Abstract]   [Full Text] [Related]  

  • 15. Eosinophilic pleural effusion associated with the addition of sodium valproate.
    Fernández-Pérez R; Alvarez-Dobaño JM; Suárez-Antelo J; Codesido-Barcala R; Carballal-Calvo F; Arrojo-Romero M; de Leon J
    J Clin Psychopharmacol; 2009 Jun; 29(3):310-1. PubMed ID: 19440094
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of sodium valproate on behavioral disturbances in elderly outpatients with dementia.
    Mizukami K; Hatanaka K; Ishii T; Iwakiri M; Sodeyama N; Tanaka Y; Asada T
    Geriatr Gerontol Int; 2010 Oct; 10(4):324-6. PubMed ID: 20887626
    [No Abstract]   [Full Text] [Related]  

  • 17. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
    McIntyre RS; Konarski JZ; Jones M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine.
    Atmaca M; Yildirim H; Ozdemir H; Ogur E; Tezcan E
    Psychol Med; 2007 Jan; 37(1):121-9. PubMed ID: 17094813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus guidelines outline drug selection and sequencing options for bipolar disorder.
    Rep Med Guidel Outcomes Res; 2000 May; 11(10):1-2, 5. PubMed ID: 11770548
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjunctive Valproic Acid in Management-Refractory Hyperactive Delirium: A Case Series and Rationale.
    Sher Y; Miller AC; Lolak S; Ament A; Maldonado JR
    J Neuropsychiatry Clin Neurosci; 2015; 27(4):365-70. PubMed ID: 25803136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.